Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Comprehensive Molecular Profiling Matches Pediatric Patients to Therapies

By LabMedica International staff writers
Posted on 22 Oct 2020
A major challenge of using a comprehensive profiling approach for precision medicine is separating pathogenic from non-pathogenic molecular changes within a tumor.

A program has been presented of the first systematic evaluation of the utility and early clinical effects of a comprehensive molecular profiling platform to identify clinically significant variants relevant to the biology of the tumor, diagnosis, clinical management, or prognosis. More...


Oncologists at the Children’s Cancer Institute (Kensington, Australia) analyzed 252 tumors from high-risk pediatric patients with cancer. These patients typically have aggressive tumors, but have few treatment options, or relapsed or refractory disease despite having undergone standard therapy. The team used tumor and germline whole genome sequencing (WGS) and RNA sequencing (RNAseq) across all the tumors from these high-risk pediatric patients with cancer.

The analysis identified 968 reportable molecular aberrations, 39.9% through WGS and RNA-seq, 35.1% through WGS only, and 25% through RNA-seq. Of these patients, 93.7% had at least one germline or somatic aberration, 71.4% had molecular aberrations that could be treated with a targeted therapy, and 5.2% had a change in diagnosis. The investigators also noted that WGS identified pathogenic cancer-predisposing variants in 16.2% of the patients. When they conducted methylome analysis in 76 central nervous system tumors, diagnosis was confirmed in 71.1% of patients and contributed to a change of diagnosis in two patients.

The scientists sought to identify non-coding driver variants linked to unexplained gene expression changes, and identified 67 established or novel driver fusions using integrated WGS and RNA-seq. The most frequent were EWSR1 rearrangements, PAX3-FOXO1, and ASPCR1-TFE3 in Ewing's sarcoma, alveolar rhabdomyosarcoma, and alveolar soft part sarcoma, respectively. They noted that there were 15 likely kinase-activating fusions, including six NTRK fusions, and that other fusions highlighted new tumor biology.

When the investigators looked for therapeutically actionable single-nucleotide variants (SNVs), copy number variants (CNVs), and structural variants, they found them clustered most frequently in RTK signaling, MAP kinase signaling, and PI3K-mTOR signaling pathways. RTKs were activated by point mutations, high copy number gains, or fusions. PI3K-mTOR variants included known activating PIK3CA mutations or loss-of-function mutations and deletions affecting PTEN, PTPN11, PIK3R1, PIK3R2, MTORC1, and MTORC2. The team also recurrently observed potentially targetable variants in epigenetic regulation genes and in the chromatin-remodeling gene PBRM1.

The authors concluded that this was the first estimate of the prevalence of germline mutations driving high-risk pediatric cancer in the Australian population based on tumor-germline WGS. WGS was critical for the assignment of pathogenicity to several variants, notably where somatic features, such as mutation signatures, tumor mutational burden (TMB) and second-hit mutations, were instrumental in identifying the underlying germline mutation(s). The study was published on October 5, 2020 in the journal Nature Medicine.

Related Links:
Children’s Cancer Institute


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Legionella Pneumophila Test
CHORUS Legionella Urinary Antigen
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.